Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19421191 | 0.86 | ALDH1A1 (0.41) | CYP2C9KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL18960364 | 0.84 | KDM4E (0.41) | CYP2C9KDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL15711100 | 0.84 | KDM4E (0.41) | CYP2C9KDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL19427233 | 0.84 | CYP2C9 (0.37) | CYP2C9KDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL18959144 | 0.84 | CYP2C9 (0.37) | CYP2C9KDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL20261365 | 0.81 | CYP2C9 (0.35) | CYP2C9KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL25712271 | 0.76 | CYP2C9 (0.33) | CYP2C9ALDH1A1MEN1KMT2A | |
| SCHEMBL20261585 | 0.76 | KMT2A (0.42) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL18959027 | 0.74 | MEN1 (0.34) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL16646886 | 0.72 | MEN1 (0.31) | CYP2C9ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| WO-2017100668-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | CYP2C9 2811/4885KDM4E 1762/4885LMNA 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.